Expert Opinion on Therapeutic Targets (ISSN 1472-8222 [print], 1744-7631 [electronic]) is a MEDLINE-indexed, peer-reviewed, international subscription-based journal publishing review articles and original papers on novel molecular targets, providing expert opinion on the scope for future drug development and the impact on drug discovery.

The journal evaluates molecules, signalling pathways, receptors and other therapeutic targets and their potential as candidates for drug development. Articles in this journal focus on the molecular level and early preclinical studies. Articles should not include clinical information including specific drugs and clinical trials.

The Editors welcome:

    Reviews covering novel disease targets at the molecular level and information on early preclinical studies and their implications for future drug development.
    Articles should not include clinical information including specific drugs and clinical trials.
    Original research papers reporting results of target selection and validation studies and basic mechanism of action studies for investigative and marketed drugs.

The audience consists of scientists, managers and decision makers in the pharmaceutical industry, academic researchers working in the field of molecular medicine and others closely involved in R&D.

Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.

Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Therapeutic Targets, part of the Expert Collection brand.

EDITOR IN CHIEF:
Daniele Santini - University Campus Bio-Medico, Rome, Italy

EDITORIAL BOARD
David Begley: Kings College, London, England, UK
Paul Caron: Vertex Pharma, Cambridge, MA, USA
Athar Chishti: Tufts University School of Medicine, MA, USA 
William Cho: Queen Elizabeth Hospital, Hong Kong
Jesus Egido: Universidad Autonoma de Madrid, Madrid, Spain
Peter Illes: University of Leipzig, Germany
Stephen F Kingsmore: Rady Children's Institute for Genomic Medicine, San Diego, California, USA
James McCubrey: Brody School of Medicine, Greenville, NC, USA
Dimitri Mikhailidis - University College London, England, UK
Ryuichi Morishita: Osaka University, Osaka, Japan
Joe O'Connell: University Hospital, Ireland
Michael Palfreyman: Amgen, NV, Belgium
Kim Rainsford: Sheffield Hallam University, Sheffield, England, UK
Simon Robson: Beth Israel Deaconess Medical Centre, Boston, MA, USA
Tomi Sawyer: Pfizer, Cambridge, MA, USA
Uday B Saxena: Kareus Therapeutics, Atlanta, GA, USA
J Marc Simard: University of Maryland School of Medicine, USA
Roberto Solari: GlaxoSmithKline, UK
Thomas Zollner: Bayer, Berlin, Germany